Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men

dc.contributor.authorOettel, Michaelen_US
dc.contributor.authorFlamigni, Carloen_US
dc.contributor.authorCostantino, Antoniettaen_US
dc.contributor.authorMeriggiola, M. Cristinaen_US
dc.contributor.authorMorselli-Labate, Antonio M.en_US
dc.contributor.authorHuebler, Dorisen_US
dc.contributor.authorBremner, William J.en_US
dc.contributor.authorBertaccini, Alessandroen_US
dc.contributor.authorKaufmann, Guenteren_US
dc.date.accessioned2008-10-17T20:43:14Z
dc.date.available2008-10-17T20:43:14Z
dc.date.issued2002-05en_US
dc.description.abstractAndrogen-progestin combinations are promising male contraceptive regimens. Optimization of these regimens includes the development of new progestins with more favorable biological properties. In this context we tested the effects of the progestin dienogest (DNG) on reproductive hormones and metabolic parameters in men. After a 3-wk control period, 25 men were randomly assigned to receive daily doses of 2, 5, or 10 mg DNG or placebo and 10 mg cyproterone acetate for 21 d (n = 5 subjects/group). Subjects were followed for 2 wk after cessation of hormone administration. Weekly blood samples, physical examinations, hormone and chemistry measurements, semen analysis, and sexual/behavioral assessments were performed. These parameters were compared among study groups and within each group at different time points throughout the study periods. DNG and cyproterone acetate administration resulted in profound suppression of gonadotropins and T with no change in SHBG levels. No adverse effects were detected in any subject. Hormone levels returned to baseline after stopping hormone intake. DNG is a potent suppressor of gonadotropins and T in men and does not induce adverse effects over a 21-d administration. DNG is a promising progestin to be used in clinical trials for male contraception.en_US
dc.identifier.citationJ Clin Endocrinol Metab. 2002 May;87(5):2107-13en_US
dc.identifier.urihttp://hdl.handle.net/1773/4465
dc.language.isoen_USen_US
dc.publisherEndocrine Societyen_US
dc.subjectandrologyen_US
dc.subjectgonadotropinsen_US
dc.subject5-alpha reductase inhibitorsen_US
dc.subjectmale contraceptionen_US
dc.subjecttestosteroneen_US
dc.subject.meshNandrolone, administration & dosage, adverse effects, analogs & derivatives, pharmacologyen_US
dc.subject.meshHumansen_US
dc.subject.meshSpermatogenesis, drug effectsen_US
dc.subject.meshReference Valuesen_US
dc.subject.meshHormones, blooden_US
dc.subject.meshResearch Support, Non-U.S. Gov'ten_US
dc.subject.meshMaleen_US
dc.subject.meshAdulten_US
dc.subject.meshPenile Erection, drug effectsen_US
dc.subject.meshGonadotropins, antagonists & inhibitorsen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshContraceptive Agents, Male, administration & dosage adverse effects, pharmacologyen_US
dc.subject.meshTestosterone, antagonists & inhibitorsen_US
dc.titleTwenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal menen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
JCEM_2002_TwentyOneDay_Administration.pdf
Size:
285.95 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.85 KB
Format:
Plain Text
Description: